Tysabri Clinical Trials Could Resume Before Product Re-Enters Market

Clinical trials for Biogen Idec/Elan's Tysabri (natalizumab) could resume before completion of discussions on whether the multiple sclerosis therapy should return to the market, Biogen Idec said during a July 26 earnings call

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet